We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Smartphone-Based Optical Imaging Offers Onsite Diagnostics

By LabMedica International staff writers
Posted on 09 Feb 2017
A novel smartphone-based optical imaging and molecular assay system permits on-site diagnostics and facilitates transfer of molecular diagnostic data from the point-of-care (POC) to the point-of-expertise, providing a cost-effective means for molecular diagnostics even in resource-limited settings.

The device, which can image and analyze specific DNA sequences and genetic mutations in tumor cells and tissue samples without prior DNA extraction, was developed through the collaborative efforts of a group of investigators at the University of California, Los Angeles, Stockholm University, and Uppsala University.

The investigators used a three-dimensional printer to produce a lightweight optical attachment to be used with a standard smartphone camera. The device is able to capture multi-color fluorescence and bright-field images of the same quality as those obtained by traditional light microscopy.

The device analyzes a tissue or cell sample in a dedicated container by recording multi-mode images of the sample during processing and feeding the data to an algorithm. The algorithm automatically analyzes the images to read the sequenced bases of the extracted tumor DNA and identifies genetic mutations directly inside the tumor tissue.

“It is very important to have these molecular testing approaches at a doctor’s office or where care is being given,” said senior author Dr. Mats Nilsson, professor of biochemistry and biophysics at Stockholm and Uppsala Universities. “Oftentimes, advanced lab-based testing is performed at major hospitals, which is limiting, as not everyone has access to a hospital that can perform these tests.”

The device was described in detail in the January 17, 2017, online edition of the journal Nature Communications.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Gold Member
Hybrid Pipette
SWITCH
Clinical Chemistry System
P780

Latest Technology News

AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
08 Feb 2017  |   Technology

AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
08 Feb 2017  |   Technology

AI Model Achieves Breakthrough Accuracy in Ovarian Cancer Detection
08 Feb 2017  |   Technology



GLOBE SCIENTIFIC, LLC